Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering Co. (NASDAQ:IMRX – Get Free Report) has received a consensus recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports.One research ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Overview: Immuneering Corporation is a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients, with a market cap of $65.83 million. Operations ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease ...

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better ...

(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with Regeneron Pharmaceuticals. The supply agreement supports ...

As the S&P 500 nears record highs, fueled by a surge in AI stocks and robust earnings reports, investors are keenly observing opportunities across various market segments. The term 'penny stocks' ...